[
ELAHERE ® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
[og_img]
https://www.investing.com/news/press-releases/elahere–mirvetuximab-soravtansinegynx-shows-consistent-survival-benefit-in-longterm-analysis-for-certain-ovarian-cancer-patients-93CH-3930732
Investing.com
ELAHERE ® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Related articles